ProCE Banner Activity

Express Points:
Changing the Course of Outcomes in NSCLC: Immunotherapy Approaches for Early-Stage Disease

Slideset Download

Download this short summary slideset to review key takeways on the use of immune checkpoint inhibition for the treatment of resectable early-stage NSCLC.

Released: January 18, 2022

Share

Faculty

Justin F. Gainor

Justin F. Gainor, MD

Associate Professor
Department of Medicine
Harvard Medical School
Assistant in Medicine
Department of Medicine
Director, Center for Thoracic Cancers
Director of Targeted Immunotherapy
Massachusetts General Hospital
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Genentech, a member of the Roche Group

Program Director Disclosure

Program Director

Justin F. Gainor, MD

Associate Professor
Department of Medicine
Harvard Medical School
Assistant in Medicine
Department of Medicine
Director, Center for Thoracic Cancers
Director of Targeted Immunotherapy
Massachusetts General Hospital
Boston, Massachusetts

Justin F. Gainor, MD, has disclosed that he has received consulting fees from Ariad/Takeda, Agios, Amgen, Array, AstraZeneca, Blueprint, Bristol-Myers Squibb, EMD Serono, Genentech, Gilead Sciences, Incyte, Loxo/Lilly, Merck, Novartis, Oncorus, Pfizer, and Regeneron; funds for research support from Ariad/Takeda, Genentech/Roche, and Novartis; and funds for research support paid to his institution from Adaptimmune, Alexo, Array Biopharma, AstraZeneca, Blueprint, Bristol-Myers Squibb, Genentech, Jounce, Merck, Moderna, Novartis, and Tesaro.